Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Creative Capital Management Investments LLC

Creative Capital Management Investments LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5,308.3% in the 3rd quarter, Holdings Channel reports. The fund owned 649 shares of the medical research company’s stock after buying an additional 637 shares during the period. Creative Capital Management Investments LLC’s holdings in Amgen were worth $209,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Meyer Handelman Co. lifted its stake in shares of Amgen by 7.2% in the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock valued at $40,566,000 after purchasing an additional 8,700 shares during the period. EP Wealth Advisors LLC raised its position in shares of Amgen by 11.0% in the first quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock worth $6,758,000 after acquiring an additional 2,353 shares during the period. BNP Paribas purchased a new stake in shares of Amgen during the 1st quarter worth about $4,772,000. Stanley Laman Group Ltd. acquired a new stake in shares of Amgen during the 2nd quarter valued at about $3,354,000. Finally, Verity & Verity LLC increased its stake in shares of Amgen by 2.7% in the 2nd quarter. Verity & Verity LLC now owns 82,368 shares of the medical research company’s stock valued at $25,736,000 after purchasing an additional 2,182 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Down 0.3 %

Shares of NASDAQ:AMGN opened at $319.22 on Friday. The company has a market capitalization of $171.53 billion, a price-to-earnings ratio of 40.87, a PEG ratio of 2.84 and a beta of 0.61. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85. The business has a 50-day moving average price of $324.47 and a 200 day moving average price of $315.19. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 181.58%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same period last year, the business earned $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.48 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.82%. Amgen’s dividend payout ratio is currently 115.24%.

Analyst Ratings Changes

AMGN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. Barclays boosted their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Truist Financial downgraded shares of Amgen from a “buy” rating to a “hold” rating and increased their price objective for the company from $320.00 to $333.00 in a report on Monday, October 14th. Finally, TD Cowen boosted their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average price target of $333.50.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.